Seven recent developments in fillers, injectables

Study findings that Kybella may be an alternative to surgical treatment for submental fat and that repeated Botox treatments improved glabellar lines at rest were among developments in injectables and fillers reported during the summer on Healio.com.

Other developments included the FDA’s approval of the marketing of Juvéderm Volbella XC for lip augmentation and correcting perioral rhytids in adults:

Kybella may be an effective alternative to surgical treatment for submental fat

Kybella demonstrated efficacy in treating submental fat, and may be an alternative to surgical treatment, according to recently published study results.

Shannon Humphrey, MD, of the University of British Columbia and Carruthers & Humphrey, Vancouver, British Columbia, and colleagues conducted a phase 3, double-blind trial of 516 adults (86.2% women; mean age, 47.9 years; mean BMI, 29.3 kg/m2) with moderate-to-severe submental fat. Patients were randomly assigned to Kybella (deoxycholic acid, Allergan), also known as ATX-101, or placebo. Read more

Repeated Botox treatments improve glabellar lines at rest

Patients with mild glabellar lines at rest achieved elimination of the resting lines following repeated Botox treatment, according to recently published study results.

Alastair Carruthers

Alastair Carruthers, MD, of the department of dermatology and skin science, University of British Columbia, Vancouver, and colleagues extracted data from a 1-year repeat treatment measurement including two 4-month randomized, placebo-controlled double-blind clinical studies followed by an 8-month open-label study. Read more

Twofold injection volume using Dysport effective in treating glabellar lines

A twofold injection volume of Dysport, compared with the labeled injection volume, to deliver the same unit dose was effective and safe in treating glabellar lines in women, according to recently published study results.

Researchers studied 62 women, aged 30 to 63 years, who received one of two different injection volumes to deliver the same unit dose of of Dysport (abobotulinumtoxinA, Galderma), marketed as Azzalure (Ipsen Biopharm Limited) in Europe for treating glabellar lines. Read more

FDA approves Juvéderm Volbella XC for lip augmentation, perioral rhytids

The FDA has approved marketing of Juvéderm Volbella XC for lip augmentation and correcting perioral rhytids in adults, according to a press release from Allergan.

Juvéderm Volbella XC (hyaluronic acid) gel was found to increase lip fullness and soften the appearance of perioral lines in the majority of patients in clinical trials, with results lasting through one year, according to the release. Read more

Restylane Lyft effective up to 12 months in midface deficiency corrections

Treatment of midface deficiencies with Restylane Lyft was effective and well-tolerated with results lasting up to 12 months, according to study results.

Researchers conducted a 15-month trial of 200 patients with mild-to-substantial loss of midface fullness (92% women; mean age, 52.9 years) who were randomly assigned to Restylane Lift (large gel particle hyaluronic acid with lidocaine [LGP-HAL], Galderma Laboratories; n = 150 patients) or no treatment (control; n = 50). Read more

FACE-Q finds increased patient satisfaction regardless of neurotoxin used for glabellar rhytids

The FACE-Q, a patient-reported outcome instrument, demonstrated that patients were satisfied with overall facial and age appearance after neuromodulation of glabellar rhytids, regardless of which neurotoxin was injected, according to published study results.

“Our work clearly demonstrates what we as plastic surgeons have known all along, namely, that minimally invasive aesthetic interventions such as neuromodulation, can provide significant physical and psychological benefits to our patients,” Ivona Percec, MD, PhD, of the division of plastic surgery, University of Pennsylvania, Perelman Center for Advanced Medicine in Philadelphia, told Healio.com. Read more

Filler rhinoplasty produces short-term outcomes comparable with surgery

Filler rhinoplasty produced temporary outcomes that were comparable to surgical augmentation rhinoplasty, according to recently published study results.

Researchers in Seoul, South Korea, retrospectively reviewed the records of 242 patients (91.3% female; mean age, 31 years) who revisited a clinic between 2 and 8 weeks after initial hyaluronic acid filler rhinoplasty. Read more